A revised international prognostic score system for Waldenström’s macroglobulinemia

• Published in: Leukemia 2019-11, Vol.33 (11), p.2654-2661
• Main Authors: Kastritis, Efstathios, Morel, Pierre, Duhamel, Alain, Gavriatopoulou, Maria, Kyrtsonis, Marie Christine, Durot, Eric, Symeonidis, Argiris, Laribi, Kamel, Hatjiharissi, Evdoxia, Ysebaert, Loic, Vassou, Amalia, Giannakoulas, Nikolaos, Merlini, Giampaolo, Repousis, Panagiotis, Varettoni, Marzia, Michalis, Euridyki, Hivert, Bénédicte, Michail, Michalis, Katodritou, Eirini, Terpos, Evangelos, Leblond, Veronique, Dimopoulos, Meletios A.
• Format: Article
• Language: English
• Subjects: 692/308/2779; 692/499; 692/699/1541/1990/291/1621/1915; Adult; Aged; Aged, 80 and over; Cancer Research; Critical Care Medicine; Follow-Up Studies; Hematology; Hematology - standards; Humans; Immunotherapy; Intensive; Internal Medicine; International Cooperation; Legg-Calve-Perthes disease; Macroglobulinemia; Medical Oncology - standards; Medical prognosis; Medicine; Medicine & Public Health; Middle Aged; Monoclonal antibodies; Neoplasm Staging - methods; Oncology; Patients; Physicians; Practice; Prognosis; Proportional Hazards Models; Prospective Studies; Recurrence; Risk; Risk Assessment; Risk factors; Rituximab; Rituximab - pharmacology; Serum albumin; Severity of Illness Index; Survival Rate; Targeted cancer therapy; Waldenstrom Macroglobulinemia - diagnosis; β2 Microglobulin
• ISSN: 0887-6924; 1476-5551
• DOI: 10.1038/s41375-019-0431-y

A staging system was developed a decade ago for patients with Waldenström’s macroglobulinemia (WM), however, since then WM treatments have changed. A revised staging system could better capture prognosis of WM patients in the chemoimmunotherapy era. We developed a revised system based on data from 492 symptomatic patients with at least 3 years and a median of 7 years of follow up while an independent validation cohort included 229 symptomatic patients. We identified age (≤65 vs 66–75 vs ≥76 years), b2-microglobulin ≥ 4 mg/L, serum albumin